Momelotinib May Become ‘No. 1 Choice’ for Second-Line Therapy in Myelofibrosis, Expert Says

Video

Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.

After demonstrating benefit in reducing anemia and splenic symptoms, momelotinib could become the optimal treatment option in the second-line setting for patients with myelofibrosis, according to Srdan Verstovsek, MD, PhD.

During the 2022 American Society of Hematology (ASH) Annual Meeting, CancerNetwork® spoke with Verstovsek, the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at the University of Texas MD Anderson Cancer Center in Houston, about findings from a pooled analysis of 3 phase 3 trials assessing momelotinib in patients with myelofibrosis.

In addition to feeling positive about the agent’s potential FDA approval in June 2023, Verstovsek stated that momelotinib could be the best treatment option for patient in the second-line setting.

Transcript:

When June of 2023 comes where we expect the decision by FDA as to whether [momelotinib should be] approved or not, I hope it will be because the study was really well done. It clearly shows the benefit in anemia and splenic symptoms. [We must quickly] find its place in the management of our patients with myelofibrosis, particularly in the setting the phase 3 randomized study was done in: the second-line setting where we struggle.

We don't have any therapy for anemia. If a patient has low platelets, this drug can be given to [them]. Of course, it can control the spleen if it has major problems. I would say that this drug may become the No. 1 choice of therapy in the second-line setting in myelofibrosis in the very near future.

Reference

Verstovsek S. Momelotinib (MMB) long-term safety: pooled data from three phase 3 randomized-controlled trials (RCTs). Presented at 2022 American Society of Hematology (ASH) Meeting and Exposition; December 10-13, 2022; abstract 4348.

Related Videos
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Related Content